Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT TNBC Vaccine Combination
NCT03175666Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Modality
- Adenoviral Vectors, Fc-Fusion Proteins, Cancer Vaccines
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, ETBX-011, ETBX-051, ETBX-061, GI-4000 in triple-negative breast cancer (TNBC), sponsored by ImmunityBio, Inc.. Planned start Dec 2017; status: withdrawn.
02
Drugs
nogapendekin alfa inbakiceptETBX-011ETBX-051ETBX-061GI-4000
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03175666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175666.